Gefarnate

Drug Profile

Gefarnate

Alternative Names: DA 688; DE-099; Geranyl farnesylacetate

Latest Information Update: 23 May 2008

Price : $50

At a glance

  • Originator Santen Pharmaceutical
  • Class Antiulcers; Terpenes; Unsaturated fatty acids
  • Mechanism of Action Mucin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Dry eyes

Most Recent Events

  • 23 May 2008 Discontinued - Phase-II for Dry eyes in Japan (Ophthalmic)
  • 09 May 2007 Phase-II clinical trials in Dry eyes in Japan (Ophthalmic)
  • 07 Jun 2005 Phase-I clinical trials in Dry eyes in Japan (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top